• Skip to primary navigation
  • Skip to main content
  • Skip to footer

LKT Labs

Biochemicals for Life Science Research

  • Products
    • New Products
    • Cancer Biology
    • Cardiovascular
    • Endocrine Signaling and Immunology
    • Metabolic and GI Pathology
    • Microbiology
    • Natural Products
    • Neuroscience
    • Peptides
    • Pharmaceutical Impurities and Derivatives
    • Stem Cell Modulators
  • Services
    • Custom Synthesis
    • Natural Product Isolation
    • Analytical Services
  • Int’l Distributors
  • Support
    • About LKT Labs
    • General Inquiry
    • Bulk Quote Request
    • Document Request
    • Technical Support
    • Catalog Request
    • Product Flyers
  • Contact Us
  • Cart
  • Login / Register
BKM120

BKM120

Product ID B4248
Cas No. 944396-07-0
Purity ≥98%
Product Unit SizeCostQuantityStock
1 mg $82.00 In stock
5 mg $228.10 In stock
Bulk Quote

Quicklinks

  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Custom Order

Description

BKM120 is an inhibitor of PI3K that is currently in clinical trials as a potential treatment for brain metastases of HER2+ breast cancer and other solid tumors. BKM120 exhibits anticancer chemotherapeutic and anti-metastatic activities, inducing G2/M phase cell cycle arrest, polyploidy, and apoptosis in glioblastoma cells. Additionally, BKM120 decreases levels of Mcl-1 and enhances TRAIL-dependent apoptosis in lung cancer cells. BKM120 also binds tubulin, inhibiting microtubule polymerization. This compound prevents invasion and epithelial-to-mesenchymal transition (EMT) in cellular and animal models of squamous cell lung cancer.

Product Info

Cas No.

944396-07-0

Purity

≥98%

Formula

C18H21F3N6O2

Formula Wt.

410.39

IUPAC Name

5-(2,6-dimorpholin-4-ylpyrimidin-4-yl)-4-(trifluoromethyl)pyridin-2-amine

Synonym

Buparlisib, NVP-BKM120

Solubility

DMSO 82 mg/mL (199.8 mM) Ethanol 2 mg/mL (4.87 mM) Water Insoluble

Appearance

White to off white powder

Shipping and Storage

Store Temp

4°C

Ship Temp

Ambient

Downloads

MSDS

B4248 MSDS PDF

Info Sheet

B4248 Info Sheet PDF

Brochures

PI3K-Akt-mTORC Pathway Booklet

References

Bonelli MA, Cavazzoni A, Saccani F, et al. Inhibition of PI3K pathway reduces invasiveness and epithelial-to-mesenchymal transition in squamous lung cancer cell lines harboring PIK3CA gene alterations. Mol Cancer Ther. 2015 May 26. [Epub ahead of print]. PMID: 26013318.

Wachsberger PR, Lawrence YR, Liu Y, et al. Hsp90 inhibition enhances PI-3 kinase inhibition and radiosensitivity in glioblastoma. J Cancer Res Clin Oncol. 2014 Feb 6. [Epub ahead of print]. PMID: 24500492.

Ando Y, Inada-Inoue M, Mitsuma A, et al. Phase I dose-escalation study of buparlisib (BKM120), an oral pan-class I PI3K inhibitor, in Japanese patients with advanced solid tumors. Cancer Sci. 2014 Jan 10. [Epub ahead of print]. PMID: 24405565.

Ren H, Zhao L, Li Y, et al. The PI3 kinase inhibitor NVP-BKM120 induces GSK3/FBXW7-dependent Mcl-1 degradation, contributing to induction of apoptosis and enhancement of TRAIL-induced apoptosis. Cancer Lett. 2013 Sep 28;338(2):229-38. PMID: 23562472.

Brachmann SM, Kleylein-Sohn J, Gaulis S, et al. Characterization of the mechanism of action of the pan class I PI3K inhibitor NVP-BKM120 across a broad range of concentrations. Mol Cancer Ther. 2012 Aug;11(8):1747-57. PMID: 22653967.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • L589921

    Loxapine Succinate

    D2 and D4 dopamine receptor inhibitor.

    ≥99%
  • E543721

    Ensartinib

    A third-generation ALK inhibitor.

    ≥98%
  • P698579

    Propantheline Bromide

    Antimuscarinic

    ≥98%
  • M1874

    3-Methyladenine

    Nucleobase (adenine) analog; DNA polymerase inh...

    ≥98%
  • R0212

    Radicicol

    Benzoquinone ansamycin; topoisomerase VI-B, HSP...

    ≥96%
  • R5602

    Ro 20-1724

    Phosphodiesterase inhibitor that produces anti-...

    ≥98%
  • N5768

    Norfloxacin

    Fluoroquinolone; topoisomerase IV and bacterial...

    ≥98%
  • S1810

    Secnidazole

    Nitroimidazole, binds DNA; nucleic acid synthes...

    ≥98%
  • N5986

    Novobiocin Sodium

    Aminocoumarin; bacterial DNA gyrase inhibitor.<...

    ≥98%
  • E5210

    Endomorphin-1

    Endogenous opioid peptide; μOr agonist.

    ≥95%
  • G2869

    Ghrelin, rat

    Endogenous peptide hormone, involved in feeding...

    ≥95%
  • I7558

    1-Isothiocyanato-9-(methylsulfenyl)-nonane

    ITC, erucin analog.

    ≥97%
  • B1752

    Benidipine Hydrochloride

    Calcium channel blocker.

    ≥98%
  • A5161

    Ampiroxicam

    Piroxicam prodrug, NSAID; COX-1/2 inhibitor.

    ≥98%
  • S0269

    SAR245409

    Pyridopyrimidinone; PI3K and mTOR inhibitor.

    ≥96%
  • T1655

    Tenoxicam Impurity 1

    Tenoxicam impurity

    ≥98%
  • A2501

    AG-1517

    EGFR inhibitor.

    ≥98%
  • G0144

    Galactosamine Hydrochloride

    Galactose-derived hexosamine sugar, component o...

    ≥98%
  • C1637

    Ceftriaxone Disodium Hemiheptahydrate

    β-lactam cephalosporin; penicillin binding pro...

    ≥98%
  • L1044

    LCL-161

    SMAC mimetic; PXR agonist, IAP inhibitor.

    ≥99%, ≥99%ee, de

Footer

  • Contact Us
  • About Us
  • Site Map
  • Terms and Conditions
LKT Laboratories, Inc.
545 Phalen Blvd.
St. Paul MN, 55130

Ph: (888)-558-5227
Fax: (888)-558-7329

©2025 LKT Laboratories, All Rights Reserved - Products for research use only